Effect of Usnic Acid on Osteoclastogenic Activity
- J Clin Med. 2018 Oct 12;7(10):345. doi: 10.3390/jcm7100345.
- 1. Department of Pharmacy, Sunchon National University, Jeonnam, Suncheon 57922, Korea. [email protected].
- 2. Korean Lichen Research Institute, Sunchon National University, Suncheon 57922, Korea. [email protected].
- 3. Department of Pharmacy, Sunchon National University, Jeonnam, Suncheon 57922, Korea. [email protected].
- 4. Department of Pharmacy, Sunchon National University, Jeonnam, Suncheon 57922, Korea. [email protected].
- 5. Department of Pharmacy, Sunchon National University, Jeonnam, Suncheon 57922, Korea. [email protected].
- 6. Korean Lichen Research Institute, Sunchon National University, Suncheon 57922, Korea. [email protected].
- 7. Department of Pharmacy, Sunchon National University, Jeonnam, Suncheon 57922, Korea. [email protected].
Osteoclasts are the only cells that can resorb bone and they are produced from monocytes/Macrophages in the presence of M-CSF and RANKL and are activated in vivo by an immune response. Usnic acid is a secondary metabolite of Lichen and has a unique dibenzofuran skeleton. It has been used for years in cosmetics, fragrances, and traditional medicines. It has a wide range of bioactivities, including anti-inflammatory, anti-bacterial, anti-cancer, anti-viral, and so on. However, the anti-osteoclastogenic activity of usnic acid has not been reported yet. In this study, we investigated whether usnic acid could affect RANKL-mediated osteoclastogenesis. Usnic acid significantly inhibited RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1, a master regulator of osteoclastogenesis. In addition, it prevented Lipopolysaccharides (LPS)-induced bone erosion in mice. Taken together, our results suggest that usnic acid might be a potential candidate for the treatment of Osteoporosis.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
-
-